Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Leukemia
  • Myelodysplastic Syndromes
  • Neuroblastoma
  • Topoisomerase II Inhibitors

abstract

  • Reducing the number of dose-intensive cycles significantly decreases the risk of SL/MDS, yielding 5-year rates matching the low range (0.4-2.2%) reported for moderate-dose combination chemotherapy regimens used against other pediatric solid tumors.

publication date

  • July 15, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4079040

Digital Object Identifier (DOI)

  • 10.1002/pbc.21931

PubMed ID

  • 19148951

Additional Document Info

start page

  • 17

end page

  • 22

volume

  • 53

number

  • 1